Biofrontera Inc. (NASDAQ: BFRI)

Biofrontera Inc. is a pharmaceutical company focused on the research development and commercialization of innovative dermatological treatments. The company specializes in photodynamic therapy solutions for skin conditions including actinic keratosis and other precancerous lesions. Its core activities center on bringing prescription dermatology products to market through regulatory approval and targeted sales efforts.

Biofrontera Inc. generates revenue primarily through the sale of its prescription dermatological products. The company earns income from product sales to healthcare providers and distributors who administer treatments to patients. Revenue is derived from commercializing FDA-approved therapies in the United States and select international markets.

The company operates through the following segments: Dermatology Products and Pharmaceutical Development.

• The Dermatology Products segment focuses on the commercialization and sale of approved topical treatments for skin conditions. This includes manufacturing marketing and distribution of prescription drugs such as Ameluz for photodynamic therapy. Activities involve regulatory compliance sales force management and market expansion efforts.

• The Pharmaceutical Development segment encompasses research and clinical trials for new dermatological formulations. This segment manages preclinical studies phase trials and regulatory submissions for pipeline products. It supports long term growth by advancing new candidates toward approval and market launch.

Biofrontera Inc. operates in a competitive specialty pharmaceutical landscape with established players in dermatology and photodynamic therapy. The company differentiates itself through its proprietary technology platform and focus on niche skin disease indications. Its competitive advantages include patent protected formulations and specialized knowledge in photodynamic treatment protocols.

Biofrontera Inc. serves dermatology clinics medical practices and healthcare distributors. Its products are used by dermatologists and physicians treating patients with actinic keratosis and related skin conditions. The company also works with specialty pharmacy partners to reach end users in the dermatology care setting.